GW Announces New Epidiolex® (CBD) Positive Phase 3 Data in Dravet Syndrome and Lennox-Gastaut Syndrome – Posters Presented at American Epilepsy Society Annual Meeting – – New data includes...

GW Pharmaceuticals plc Announces Epidiolex(R) (cannabidiol) Data Presentations and Educational Programs at the American Society of Epilepsy Annual Meeting –  Presentations include clinical results from Phase 3 programs in...

Pharmaceutical CBD (cannabidiol) Shows Promise for Children with Severe Epilepsy Significant seizure reduction in studies using CBD in combination with AEDs PHILADELPHIA, December 7, 2015 – Around the globe...